Latest News
IONTAS and FairJourney Biologics enter antibody discovery agreement with Quell Therapeutics
Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited (IONTAS) and FairJourney...
FairJourney Biologics Group introduces Flow Eighteen38 for protein production and antibody characterization services
Porto, Portugal, 8th February 2021: FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterization data on antibody panels and leads.
A Year in Review Interview with Antonio Parada
António Parada, CEO of FairJourney Biologics, was recently featured on TV to review last year's challenges and successes and the companies plans for continued growth and innovation into 2021.
IONTAS and FairJourney Biologics enter antibody discovery agreement with Quell Therapeutics
Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited (IONTAS) and FairJourney...
FairJourney Biologics Group introduces Flow Eighteen38 for protein production and antibody characterization services
Porto, Portugal, 8th February 2021: FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterization data on antibody panels and leads.
A Year in Review Interview with Antonio Parada
António Parada, CEO of FairJourney Biologics, was recently featured on TV to review last year's challenges and successes and the companies plans for continued growth and innovation into 2021.
